FutureCeuticals and Aura Scientific Settle Patent Dispute, Transition to CognatiQ

FutureCeuticals and Aura Scientific Resolve Patent Dispute

FutureCeuticals, Inc. (commonly referred to as FC) and Aura Scientific have announced a resolution to the ongoing patent and trademark dispute concerning coffee fruit extract. This conflict involved claims surrounding Aura's ingredient, NeuroRush®, and FutureCeuticals' CognatiQ® and NeuroFactor® products.

The settlement is a significant win for FutureCeuticals, as it validates the company's intellectual property rights. J. Randal Wexler, the Vice President and General Counsel of FutureCeuticals, commented positively on the acknowledgment from Aura regarding the validity of their intellectual property. This acknowledgment not only highlights the value of FutureCeuticals' innovations in cognitive health but also reinforces the company's commitment to protecting its intellectual assets, which secures future investments in clinical research and innovation.

Although this resolution marks the end of Aura's use of the ingredient NeuroRush®, it signifies the beginning of a new collaborative journey between the two companies. Aura is currently in the process of transitioning to CognatiQ®, which is seen as a suitable replacement for NeuroRush. Kyle Seymour, Head of Product Development at Aura, expressed enthusiasm for introducing CognatiQ to both existing and potential customers, emphasizing that it comes with robust clinical backing and scientific expertise from FutureCeuticals.

This transition is positioned as a win-win scenario for both organizations. Both parties agree that this collaboration will open up new avenues for marketing ingredients with clear health benefits. Aura's growing influence in the wellness market, combined with FutureCeuticals' strong reputation in clinical efficacy, aligns perfectly with their mutual goal of supporting brands seeking scientifically backed ingredients.

Seymour highlighted the importance of their cooperation, suggesting that focusing on customer-centric projects will allow the two companies to leverage their respective strengths. By combining Aura's product development experience with FutureCeuticals' portfolio of clinically proven ingredients, they aim to create new opportunities that benefit consumers and the broader wellness industry.

About FutureCeuticals, Inc.
FutureCeuticals is a leader in the research, development, and manufacturing of fruit, vegetable, and grain-based powders and extracts. Products like CognatiQ® and NeuroFactor® are available exclusively through FutureCeuticals.

About Aura Scientific
Aura Scientific specializes in innovation related to ingredients, focusing on the research, development, and marketing of unique nutraceutical components for dietary supplements. Their portfolio includes products like EndoFlo™ and ProtoTest™, designed to support consumer wellness applications.

Conclusion
This settlement marks a positive step for both FutureCeuticals and Aura Scientific, emphasizing their commitment to quality and scientific innovation in the health industry. With the transition to CognatiQ®, both companies express confidence in their collaborative future and the potential for delivering exceptional ingredient solutions in the wellness market.